Is Neurogene Inc. (NGNE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 4.1% / 30% | 91.0% / 30% | 0.2% / 30% | 915.35% / 5% | ✗ NOT HALAL |
| DJIM | 4.1% / 33% | 91.0% / 33% | 0.2% / 33% | 915.35% / 5% | ✗ NOT HALAL |
| MSCI | 4.2% / 33% | 93.1% / 33% | 0.2% / 33% | 915.35% / 5% | ✗ NOT HALAL |
| S&P | 4.1% / 33% | 91.0% / 33% | 0.2% / 33% | 915.35% / 5% | ✗ NOT HALAL |
| FTSE | 4.2% / 33% | 93.1% / 33% | 0.2% / 50% | 915.35% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -31.4% | |
| Return on Assets (ROA) | -20.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$71M |
| Free Cash Flow | -$71M |
| Total Debt | $14M |
| Debt-to-Equity | 3.7 |
| Current Ratio | 16.6 |
| Total Assets | $336M |
Price & Trading
| Last Close | $21.41 |
| 50-Day MA | $19.53 |
| 200-Day MA | $21.27 |
| Avg Volume | 168K |
| Beta | 1.7 |
|
52-Week Range
$6.88
| |
About Neurogene Inc. (NGNE)
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Neurogene Inc. (NGNE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Neurogene Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Neurogene Inc.'s debt ratio?
Neurogene Inc.'s debt ratio is 4.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 4.2%.
What are Neurogene Inc.'s key financial metrics?
Neurogene Inc. has a market capitalization of $317M, and revenue of $925,000. Return on equity stands at -31.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.